Pds biotech to participate at upcoming investor conferences

Florham park, n.j., may 17, 2022 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the company's proprietary versamune® and infectimune™ t-cell activating technologies, today announced that its management will present at the h.c. wainwright global investment conference and the ld micro invitational and will participate at the ubs healthcare virtual one-on-one day.
PDSB Ratings Summary
PDSB Quant Ranking